<DOC>
	<DOCNO>NCT01368068</DOCNO>
	<brief_summary>Many perimenopausal woman experience severe mood symptom first time life , past psychiatric history . The importance clearly identify treat disorder increasingly refer `` perimenopausal depression '' highlight wide-reaching impact live woman suffer . This minor short term mood disturbance ; severe depressive illness , need effective early treatment . Relationships , employment , participation social role individual well-being disrupt combination mood , hormonal physical change associate transition menopause . The term `` perimenopausal depression '' denote onset depression coincide onset reproductive hormone change . Many woman type depression experience serious long term debilitating symptom . Treatment commonly draw traditional approach management major depression include use antidepressant selective serotonin reuptake inhibitor ( SSRIs ) first line response . However , standard treatment perimenopausal depression use antidepressant show small improvement best worst , associate severe side effect . Some SSRIs show less effective postmenopausal woman compare child bearing age woman . Hormone treatment directly target fluctuate reproductive hormone system ( particular estrogen ) administration compound tibolone , significant potential good overall treatment . To date , still lack clear clinical evidence best approach biological treatment woman perimenopausal depression . The project propose conduct 12-week randomise control trial ( RCT ) 2.5 mg/day tibolone compare 10mg/day escitalopram ( SSRI target serotonin action ) compare placebo discover best treatment approach hitherto understudied depression affect large proportion woman late forty fifty .</brief_summary>
	<brief_title>Investigation Tibolone Escitalopram Perimenopausal Depression</brief_title>
	<detailed_description>All woman experience menopause significant number suffer ongoing , severe depression begin major hormone fluctuation middle stage life . The number woman experience menopause related major depression impact depression woman 's life , work family grossly underestimated . We propose conduct clinical trial new hormone treatment woman severe depression relate menopause , compare standard antidepressant medication . Longitudinal epidemiological study show many woman experience significant physical psychological change approach menopause long time follow . Vasomotor symptom ( hot flush , night sweat ) , sleep disturbance change libido common , impact significantly quality life , social personal well-being . However , major reason many woman seek help menopause clinic doctor , depression anxiety symptom . Many perimenopausal woman experience severe mood symptom first time life , past psychiatric history . The importance clearly identify treat disorder increasingly refer `` perimenopausal depression '' highlight wide-reaching impact live woman suffer . This minor short term mood disturbance ; severe depressive illness , need effective early treatment . Relationships , employment , participation social role individual well-being disrupt combination mood , hormonal physical change associate transition menopause . The term `` perimenopausal depression '' denote onset depression coincide onset reproductive hormone change . Many woman type depression experience serious long term debilitating symptom . Treatment commonly draw traditional approach management major depression include use antidepressant selective serotonin reuptake inhibitor ( SSRIs ) first line response . However , standard treatment perimenopausal depression use antidepressant show small improvement best worst , associate severe side effect . Some SSRIs show less effective postmenopausal woman compare child bearing age woman . Hormone treatment directly target fluctuate reproductive hormone system ( particular estrogen ) administration compound tibolone , significant potential good overall treatment . To date , still lack clear clinical evidence best approach biological treatment woman perimenopausal depression . The project propose conduct 12-week randomise control trial ( RCT ) 2.5 mg/day tibolone compare 10mg/day escitalopram ( SSRI target serotonin action ) compare placebo discover best treatment approach hitherto understudied depression affect large proportion woman late forty fifty .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Females currently physically well 45 55 year age Current DSMIV diagnosis depression disorder Able give inform consent Perimenopausal determine symptom profile Stages Reproductive Aging Workshop gonadal hormonal profile Known abnormality hypothalamicpituitary gonadal axis , thyroid dysfunction , central nervous system tumour , active past history venous thromboembolic event , breast pathology , undiagnosed vaginal bleeding abnormal Pap smear result previous 2 year . Patients significant unstable medical illness epilepsy diabetes know active cardiac , renal liver disease ; presence illness cause immobilisation . Patients receive treatment depression include antidepressant medication , electroconvulsive therapy ( ECT ) / Transcranial Magnetic Stimulation ( TMS ) , formal psychotherapy counselling , within past 6 month Patients experience severe melancholia , neurovegetative symptom current suicidality necessitate acute hospitalisation intensive psychiatric treatment . Patients psychotic symptom past history severe mental illness include schizophrenia , bipolar disorder . Use form estrogen , progestin androgen hormonal therapy , antiandrogen include tibolone use phytoestrogen supplement powder tablet Pregnancy / Lactation Smoking cigarettes nicotine product . illicit drug use 3 standard drink per day</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Perimenopause</keyword>
	<keyword>Depression</keyword>
</DOC>